^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Immunostimulant

    Related drugs:
    16h
    A Study to Learn Safety and Immune Response to Study Vaccine -RSVpreF in Adults at High Risk of Severe RSV Disease. (clinicaltrials.gov)
    P3, N=130, Not yet recruiting, Pfizer
    New P3 trial
    19h
    A Phase 3 Study to Assess the Immune Response And Safety Of Rmenb+Omv Nz In Primed Healthy Participants (10 To 20 Years Old) (clinicaltrials.gov)
    P3, N=312, Completed, GlaxoSmithKline | Active, not recruiting --> Completed | N=226 --> 312
    Trial completion • Enrollment change
    20h
    IVIG for Infection Prevention After CAR-T-Cell Therapy (clinicaltrials.gov)
    P2, N=150, Recruiting, Fred Hutchinson Cancer Center | Trial primary completion date: Jul 2027 --> Jul 2028
    Trial primary completion date
    1d
    AAV immuno-gene therapy platform delivering vectorized cytokines defines a new modality for high-grade glioma treatment. (PubMed, Mol Ther Oncol)
    To enable clinical translation, we developed SRN-101, a clinical-grade AAV-hIFNβ construct with optimized potency and manufacturability, which achieved superior expression and in vivo efficacy vs. the research-grade vector. These findings establish AAV-vectorized cytokines as a durable, locally delivered immuno-gene therapy platform for high-grade gliomas.
    Journal • IO biomarker
    |
    IFNG (Interferon, gamma) • IFNA1 (Interferon Alpha 1) • IFNB1 (Interferon Beta 1)
    1d
    Neoantigen-based cancer vaccines: a mechanistic and clinical review of personalised melanoma immunotherapy. (PubMed, Front Immunol)
    Clinical data reflects this, with the mRNA vaccine mRNA-4157 (KEYNOTE-942) demonstrating a significant recurrence-free survival (RFS) benefit in the adjuvant setting...This reflects the logistical and biological complexities inherent in developing personalised vaccines, highlighting challenges in both manufacturing and subject recruitment. These remain key obstacles impeding the widespread clinical application of such vaccines.
    Review • Journal • Tumor mutational burden • IO biomarker
    |
    TMB (Tumor Mutational Burden) • CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
    |
    TMB-H
    |
    intismeran autogene (mRNA-4157)
    1d
    Safety and Immunogenicity of Ad4-HIV Envelope Vaccine Vectors in Healthy Volunteers (clinicaltrials.gov)
    P1, N=300, Recruiting, National Institute of Allergy and Infectious Diseases (NIAID) | Trial completion date: Oct 2026 --> Nov 2028 | Trial primary completion date: Oct 2026 --> Nov 2028
    Trial completion date • Trial primary completion date
    1d
    MENB-PARD: Immunogenicity and Safety of MenB Vaccine in Pediatric Patients With Autoimmune Rheumatic Diseases (clinicaltrials.gov)
    P4, N=263, Recruiting, University of Sao Paulo General Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    1d
    XPERT: A Study to Evaluate the Pharmacokinetics and Safety of XEMBIFY Versus Gamunex-C in Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (clinicaltrials.gov)
    P3, N=40, Recruiting, Grifols Therapeutics LLC
    New P3 trial
    2d
    IOV-MEL-202: A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma (clinicaltrials.gov)
    P2, N=100, Active, not recruiting, Iovance Biotherapeutics, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed • Trial initiation date
    |
    BRAF mutation • BRAF V600
    |
    Amtagvi (lifileucel)
    2d
    Autologous Tumor-Infiltrating Lymphocyte (GTE-001 Injection ) for Treatment of Patients With Advanced Lung Adenocarcinoma (clinicaltrials.gov)
    P1, N=2, Terminated, Grit Biotechnology | N=12 --> 2 | Recruiting --> Terminated; The study was terminated from a business perspective.
    Enrollment change • Trial termination
    2d
    A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella Disease and Typhoid Fever in Infants (clinicaltrials.gov)
    P2, N=537, Recruiting, GlaxoSmithKline | Not yet recruiting --> Recruiting
    Enrollment open
    2d
    Evaluate the Safety and Efficacy of BLEX 404 Oral Liquid Combined With Pemetrexed + Cisplatin Therapy (clinicaltrials.gov)
    P1/2, N=32, Not yet recruiting, Rgene Corporation | Trial completion date: Dec 2027 --> Dec 2028
    Trial completion date
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR wild-type
    |
    cisplatin • pemetrexed